Print

Raptor Pharmaceutical Inc. (RPTP) Licenses Intellectual Property Related to Parkinson's Disease From Universit√© Laval  
6/20/2012 9:20:59 AM

NOVATO, Calif., June 20, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval ("Laval"), Quebec, Canada.